[pubmed] Management of thymomatous myasthenia gravis - Case report of a rare Covid19 infection sequelae

[RSS-Bot]

Int J Surg Case Rep. 2021 Mar 13;81:105771. doi: 10.1016/j.ijscr.2021.105771. Online ahead of print.

ABSTRACT

INTRODUCTION: SARS CoV19 infection can predispose to many autoimmune and neurological conditions, thymomatous myasthenia gravis being one of them. The rarity of these case poses therapeutic dilemmas about their further management.

PRESENTATION OF CASE: A 61 year old gentleman who had covid19 infection 2 months back, presented with new onset myasthenia gravis and an anterior mediastinal mass. He was diagnosed as a case of anti acetyl choline receptor antibody positive thymomatous myasthenia gravis. The patient was posted for video assisted thoracoscopic excision of thymoma. The procedure was uneventful and patient was discharged with improvement in myasthenic symptoms. Histopathological examination confirmed the diagnosis of WHO Type A Spindle cell thymoma.

DISCUSSION: SARS CoV19 infection is associated with an array of autoimmune disorders due to various proposed phenomenon including molecular mimicry and loss of immune tolerance. Post infectious thymomatous myasthenia gravis is extremely uncommon, and can be managed with open, minimally invasive or robotic approach.

CONCLUSION: This is the first documented case of post covid19 infection thymomatous myasthenia gravis to the best of our knowledge, managed with minimally invasive thoracoscopic surgery. Further research is required for documentation of the natural history of the disease and therapeutic outcomes.

PMID:33744800 | DOI:10.1016/j.ijscr.2021.105771


Source: https://pubmed.ncbi.nlm.nih.gov/3374480 ... 6&v=2.14.3